Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) – Zacks Investment Research dropped their FY2017 earnings per share (EPS) estimates for shares of Tonix Pharmaceuticals in a note issued to investors on Wednesday. Zacks Investment Research analyst D. Bautz now expects that the company will post earnings per share of ($3.23) for the year, down from their prior forecast of ($2.96). Zacks Investment Research also issued estimates for Tonix Pharmaceuticals’ Q4 2017 earnings at ($0.74) EPS.

Other research analysts also recently issued research reports about the company. Dawson James restated a “buy” rating and issued a $9.00 target price on shares of Tonix Pharmaceuticals in a research note on Wednesday, August 23rd. Drexel Hamilton started coverage on Tonix Pharmaceuticals in a research note on Tuesday, August 22nd. They issued a “buy” rating on the stock. Aegis restated a “buy” rating on shares of Tonix Pharmaceuticals in a research note on Friday, December 1st. Finally, ValuEngine upgraded Tonix Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $8.33.

Tonix Pharmaceuticals (NASDAQ TNXP) opened at $3.50 on Monday. Tonix Pharmaceuticals has a 52 week low of $2.85 and a 52 week high of $9.40.

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Vanguard Group Inc. lifted its stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 28.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 184,377 shares of the company’s stock after acquiring an additional 41,264 shares during the quarter. Vanguard Group Inc. owned about 2.46% of Tonix Pharmaceuticals worth $799,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 17.51% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

Earnings History and Estimates for Tonix Pharmaceuticals (NASDAQ:TNXP)

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with's FREE daily email newsletter.